Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing’s Sarcoma Family Tumors

PURPOSE: Temsirolimus was combined with cixutumumab, a fully human IgG1 monoclonal antibody directed at the insulin growth factor-1 receptor (IGF-1R). EXPERIMENTAL DESIGN: Patients received cixutumumab, 6 mg/kg IV weekly, and temsirolimus, 25 mg-37.5 mg IV weekly (4-week cycles), with restaging afte...

Full description

Saved in:
Bibliographic Details
Main Authors: Naing, Aung, LoRusso, Patricia, Fu, Siqing, Hong, David S., Anderson, Pete, Benjamin, Robert S., Ludwig, Joseph, Chen, Helen X., Doyle, Laurence A., Kurzrock, Razelle
Format: Artigo
Language:Inglês
Published: 2012
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3875297/
https://ncbi.nlm.nih.gov/pubmed/22465830
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-0061
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items